SAMSUNG BIOLOGICS Announces Capital Increase
삼성바이오로직스
207940
Signal Score
Historical Avg Return (5d)
+0.00%
Data Coverage
100%n=2809
Risk-adjusted indicator based on 2809 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
NEGATIVE
Key Numbers
- • Discount Rate: 15%
- • Par Value per Share: 2,500 KRW
- • Employee Stock Ownership Association Allocation: 20% (454,000 Shares)
- • Shareholder Allocation Ratio: 0.0392737657 shares per existing share
- • Board Resolution Date: August 28, 2026
AI Analysis Summary
SAMSUNG BIOLOGICS announced a decision for a paid-in capital increase via a shareholder allocation method with a 15% discount rate. The par value per share is 2,500 KRW. The Employee Stock Ownership Association will be preferentially allocated 20% (454,000 shares) of the total new shares. Existing shareholders will receive 0.0392737657 new shares per existing share. The final offering price will be determined based on a formula considering 1st and 2nd offering prices, with a floor of 60% of the reference price and the par value. This capital increase could lead to dilution for existing shareholders, although the specific number of new shares and total funding amount are not yet disclosed. The purpose of the funds is also not specified in this initial report.
How This Event Is Evaluated
Capital Raise Evaluation
Capital raise events are evaluated by estimating dilution pressure, funding purpose, pricing terms, and impact on existing shareholders.
AI is used to interpret disclosures and extract structured data.
Signal scores are generated using event-specific methodologies and quantitative models.
- Potential dilution rate
- Issuance or conversion price
- Funding purpose
- Shareholder value impact
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.